Anixa Biosciences’ (ANIX) “Buy” Rating Reiterated at D. Boral Capital

Anixa Biosciences (NASDAQ:ANIX)‘s stock had its “buy” rating restated by stock analysts at D. Boral Capital in a note issued to investors on Wednesday,Benzinga reports. They presently have a $10.00 price objective on the stock. D. Boral Capital’s target price would indicate a potential upside of 271.75% from the stock’s previous close.

Other analysts also recently issued reports about the company. Wall Street Zen downgraded Anixa Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Anixa Biosciences in a research note on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $8.50.

Anixa Biosciences Price Performance

Shares of ANIX opened at $2.69 on Wednesday. The stock has a 50-day moving average of $2.84 and a 200-day moving average of $3.50. The company has a market cap of $90.19 million, a PE ratio of -8.15 and a beta of 0.57. Anixa Biosciences has a one year low of $2.33 and a one year high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last issued its earnings results on Monday, March 9th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.01. Analysts expect that Anixa Biosciences will post -0.41 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Arnold M. Baskies acquired 10,000 shares of the firm’s stock in a transaction on Wednesday, January 28th. The stock was purchased at an average price of $3.04 per share, for a total transaction of $30,400.00. Following the purchase, the director owned 135,000 shares in the company, valued at approximately $410,400. This represents a 8.00% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 26.40% of the company’s stock.

Institutional Investors Weigh In On Anixa Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in ANIX. 683 Capital Management LLC purchased a new stake in Anixa Biosciences in the 4th quarter valued at about $355,000. ExodusPoint Capital Management LP purchased a new stake in Anixa Biosciences in the 4th quarter valued at about $293,000. Susquehanna International Group LLP increased its stake in Anixa Biosciences by 378.4% in the 3rd quarter. Susquehanna International Group LLP now owns 80,387 shares of the company’s stock valued at $265,000 after buying an additional 63,584 shares during the last quarter. Virtu Financial LLC purchased a new stake in Anixa Biosciences in the 4th quarter valued at about $161,000. Finally, State Street Corp increased its stake in Anixa Biosciences by 32.0% in the 4th quarter. State Street Corp now owns 159,040 shares of the company’s stock valued at $496,000 after buying an additional 38,540 shares during the last quarter. Hedge funds and other institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.